IDXX Idexx Laboratories

Q3 2025 10-Q

Filed: Nov 3, 2025Period ending Sep 30, 2025

Health Care

In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR

Idexx Laboratories (IDXX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• No quarterly revenue or YoY change information disclosed in this section
• No profitability or margin percentages provided

+3 more insights

Risk Factors

• No material changes in risk factors since 2024 Annual Report
• Ongoing risks include business, financial condition, or future results impact

+1 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.1B

Net Income

$275M

Gross Margin

61.8%

Operating Margin

32.1%

Net Margin

24.8%

ROE

17.6%

Total Assets

$3.4B

Source: XBRL data from Idexx Laboratories Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Idexx Laboratories Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Idexx Laboratories

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.